New pill aims to stop kidney stones before they start

NCT ID NCT06932146

Completed Disease control Sponsor: Lilac Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called LLX-424 in 51 adults who have had kidney stones before. The drug works by blocking an enzyme that makes oxalate, a key ingredient in most kidney stones. Participants took the drug or a placebo daily for 8 weeks to see if it safely lowers oxalate levels in urine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LLX-424 (a glycolate oxidase inhibitor taken as a tablet)
What this could lead to: If it works, this could lead to a new daily pill that helps prevent calcium oxalate kidney stones from forming.
What could go wrong: This is a small, early-phase trial focused on safety and lab markers, not stone prevention. The drug may not reduce stones in real life or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY STONES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Kidney Calculi nephrolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY STONES

Contacts and locations

Show contact details

Locations

Clinical Research Site #1

San Antonio, Texas, 78217, United States
Clinical Research Site #2

Saint Paul, Minnesota, 55114, United States
Clinical Research Site #3

Springfield, Missouri, 65802, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.